Things are actually going well? We'll see about that in the next 10Q when filed. I believe the 3rd quarter was due on 10/15/2017. The stock has been drifting from Pink Reporting to Pink Non-Reporting. In one review a person praised Emesyl for its effectiveness, but wondered why it wasn't available in national chains for immediate purchase. There's still no update by management on the strategic efforts to promote the product. GLTA with ITNS!
News 
Market Data 
Discover 
